^
Association details:
| Biomarker: | ALK mutation |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor) + batoprotafib (TNO155) (PTPN11 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SHP2 Inhibition with TNO155 Increases Efficacy and Overcomes Resistance of ALK Inhibitors in Neuroblastoma
Published date:
12/27/2023
Excerpt:
Here, we have assessed the efficacy of the SHP2 inhibitor TNO155 alone and in combination with the ALK-TKIs crizotinib, ceritinib, or lorlatinib for the treatment of ALK-driven neuroblastoma using in vitro and in vivo models….Moreover, treatment with TNO155 and ALK-TKIs synergistically reduced cell growth and promoted inactivation of ALK and MAPK signaling in ALK-mutant neuroblastoma cells.
DOI:
https://doi.org/10.1158/2767-9764.CRC-23-0234
